Anemocyte
- Advanced Therapies Week
- Exhibitor
- Academics
- Biotech
- Start-up
- CDMOs
- CROs
- CDMO/CMO services
- Cell banking
- Fill and finish
- Plasmid manufacturing
- Process development and validation
- COGs optimization
- Storage
- Raw materials supply
- Gene editing constucts
- Nucleic acids
- Stem Cell
- Tissue Engineering
- Immunotherapy
- Gene Therapy
- Cell Therapy
- Cell Based-IO
- Contract Development and Manufacturing Organisation/Contract Manufacturing Organisation
)
Tozaro is a biotech company leveraging molecular modelling and ML to design and develop stable and cost effective polymers that bind to proteins specifically & selectively. Our proprietary Smart Polymer™ platform utilises >500 monomeric compunds compared to biologics using ca. 20 amino acids, enabling Tozaro to mine a huge new chemical space with a cost-effective modality. We generate candidate binders with optimal properties within two months for application in a number of bioprocessing and analytical settings, for both off-the-shelf applications and tailored to specific partner needs.
Our lead Smart Polymer™ programs are novel affinity chromatography ligands for viral vectors, where downstream yields are typically poor & manufacturing innovations are urgently needed to increase patient access to transformative therapies. These include VSV-G/lentiviral vector affinity purification and pan-AAV serotype affinity purification. The Smart Polymer™ platform has broader application to generate stable, cost effective affinity ligands across the larger antibody & biologics purification market, in DNA/RNA therapeutics and in vaccine manufacturing.
Tozaro has 30 employees with expertise across in silico design, ML, advanced polymer synthesis and application development. The team is supported by venture capital investors and is located in the UK.”